Back to News
Market Impact: 0.3
AbbVie Reports Positive Phase 2 Results For Zumilokibart In Atopic Dermatitis
Source: Nasdaq
Healthcare & BiotechProduct Launches
AbbVie reported positive interim Phase 2 APEX Part B dose-regimen-finding results for investigational zumilokibart in adults with moderate-to-severe atopic dermatitis. The data support further clinical development of the therapy, representing a positive pipeline catalyst for AbbVie, although no efficacy or safety figures were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
ABBV0.70
More News
- AbbVie’s zumilokibart meets phase 2 atopic dermatitis endpoint
- AbbVie presents phase 1 data for obesity drug ABBV-295
- Google rolls out Gemini 4 Argon, its most advanced AI model
- Meta stock enjoys best month since 2022 on AI momentum
- Huawei unveils Mate 90 phones, leans on homegrown chip design to offset US curbs
- Bloomberg Tech: OpenAI Seeks $30B as Trump Backs Safety Audits